PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. (Q39767744)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Carsten Denkert

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Valentina Guarneri

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Pierfranco Conte

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

author name string

V Nekljudova

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

E Holmes

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

C Schem

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

C Sotiriou

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

M Piccart

14

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

G von Minckwitz

15

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

S Loibl

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

M Untch

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

J Baselga

16

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

13 May 2016

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Annals of Oncology

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

27

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

1519-1525

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Neoadjuvant treatment of breast cancer: maximizing pathologic complete response rates to improve prognosis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

The PIK3CA gene is mutated with high frequency in human breast cancers.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Reporting recommendations for tumor marker prognostic studies (REMARK).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Analysis of PIK3CA mutations in breast cancer subtypes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27177864

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDW197

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39767744&oldid=2090112712"